

Open Protocols [by cancer site]

Wendy's pager: 556-0034 (8 AM - 4-5 PM)

Karen's pager: 556-9068 (8:30 AM - 4:30 PM)

Vanessa's pager: 556-6839 (7:30 AM - 3:30 PM)

Almae's pager: 556-6352 (7:30 AM - 3:30 PM)

Basia's pager: 556-0052 (8:30 AM - 4 PM)

Denisha's phone: x45260 (8 AM - 3:30 PM)

Protocol	IRB #	Description	Credits:	Treatm.	Control	F/U
Cancer Site: Brain						
1. CCCWFU 97509	10-227	A Phase II Double-Blind Feasibility Study of Armodafinil for Brain Radiation-Induced Fatigue.				
CRA: Basia Lukaszcyk						
Anticipated accrual: 5						
2. ECOG E-3F05	09-203	Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas. CC credits for QOL.	1	0.5	0	
CRA: Basia Lukaszcyk						
Anticipated accrual: 5						
Cancer Site: Breast						
1. CALGB 40603	11-022	Randomized Phase II 2 X 2 Factorial Trial Of The Addition Of Carboplatin +/- Bevacizumab To Neoadjuvant Weekly Paclitaxel Followed By Dosedense Ac In Hormone Receptor-Poor/Her2-Negative Resectable Breast Cancer.				
CRA: Wendy A. Rogowski						
Anticipated accrual: 5						
2. ECOG E-2108	11-106	A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer.				
CRA:						
Anticipated accrual:						
3. Ex. Study IRB# 10-060	10-060	Clinical-pathological outcomes in minority-underserved women with breast cancer.	0	0	0	
CRA:						
Anticipated accrual:						
4. Ex. Study IRB# 211-01	211-01	Tissue Bank	0	0	0	
CRA: Wendy A. Rogowski						
Anticipated accrual:						
5. NCIC MA-32	10-203	A Phase III Randomized Trial of the Effect of Metformin Versus Placebo On Recurrence And Survival In Early Stage Breast Cancer. * See NCIC MA-32-QOL for additional CC credit for QOL component. QOL component is closed!	1	0	0	
CRA: Wendy A. Rogowski						
Anticipated accrual: 20						
6. NSABP B-43	09-066	A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected By Lumpectomy.	0	1	0	
CRA: Wendy A. Rogowski						
Anticipated accrual: 5						
7. NSABP B-47	11-059	* 0.1 CC credits for blood draw; 0.3 CC credits for Menstrual History Study (NSABP B-47-MH). A randomized phase III trial of adjuvant therapy comparing chemotherapy alone (six cycles of docetaxel plus cyclophosphamide or four cycles of doxorubicin plus cyclophosphamide followed by weekly paclitaxel) to chemotherapy plus trastuzumab in women with node-positive or high risk node negative HER2-low invasive breast cancer.	1.1	0	0	
CRA: Wendy A. Rogowski						
Anticipated accrual: 5-10						

Protocol	IRB #	Description	Credits	Treatm.	Control	F/U
8. RTOG 1014 CRA: Anticipated accrual: 2-5	10-209	A Phase II Study Of Repeat Breast Preserving Surgery And 3d-Conformal Partial Breast Re-Irradiation (PBRI) For Local Recurrence Of Breast Carcinoma.				
9. SCUSF 0806 CRA: Vanessa Barrera Anticipated accrual: 5	10-042	Phase II placebo-controlled trial of lisinopril and Coreg CR to reduce cardiotoxicity in patients with breast cancer receiving (neo)adjuvant chemotherapy with trastuzumab (Herceptin).	0	1	0	
10. SWOG S1007 CRA: Wendy A. Rogowski Anticipated accrual: 5	11-174	A Phase III, Randomized Clinical Trial Of Standard Adjuvant Endocrine Therapy +/- Chemotherapy In Patients With 1-3 Positive Nodes, Hormone Receptor-Positive And Her-2 Negative Breast Cancer With Recurrence Score (Rs) Of 25 Or Less. * 0.5 CC for QOL for the first 500 pts. Call to check (206) 652-2267 (Bill or Danica). Or (210) 614-8808	1	0.5	0	

Cancer Site: Colorectal

1. CALGB 150911 CRA: Karen Carter Anticipated accrual:		Sub-study of CALGB 80702.	0.2	0	0	
2. CALGB 60905 CRA: Karen Carter Anticipated accrual:		Sub-study of CALGB 80702	0.1	0	0	
3. CALGB 71002 CRA: Karen Carter Anticipated accrual:		Sub-study of CALGB 80702.	0	0.5	0	
4. CALGB 80702 CRA: Karen Carter Anticipated accrual: 5	10-245	A Phase III Trial Of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer. +0.2 Tr. Cred. for 150911, +0.1 Tr. Cred. for 60905 and +0.5 CC for 71002	1	0	0	
5. ECOG E-7208 CRA: Karen Carter Anticipated accrual: 4	11-028	A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy.				
6. NSABP P5 CRA: Karen Carter Anticipated accrual:	10-179	Statin Polyp Prevention Trial in Patients with Resected Colon Cancer.				
7. UIC P60 CRA: Karen Carter Anticipated accrual:	11-090	Chicago Colon Cancer Patterns of Care study				

Cancer Site: Gyne

1. GOG 0249 CRA: Basia Lukaszczyk Anticipated accrual:	10-052	Phase III Randomized Study of Pelvic Radiotherapy Versus Vaginal Cuff Brachytherapy, Paclitaxel, and Carboplatin in Patients With High-Risk Stage I or II Endometrial Carcinoma.	1	0.5	0	
2. GOG 0258 CRA: Basia Lukaszczyk Anticipated accrual: 3-5	10-151	A Randomized Phase III Trial of Cisplatin And Tumor Volume Directed Irradiation Followed By Carboplatin And Paclitaxel Vs. Carboplatin And Paclitaxel For Optimally Debulked, Advanced Endometrial Carcinoma. * CC 0.5 for QOL.	1	0.5	0	

	Protocol	IRB #	Description	Credits:	Treatm.	Control	F/U
3.	GOG 0261 CRA: Basia Lukaszcyk Anticipated accrual: 3-5	10-150	A randomized phase III trial of paclitaxel plus carboplatin versus Ifosfamide plus Paclitaxel in Chemotherapy Naïve Patients with Newly Diagnosed Stage I-IV, persistent or recurrent carcinomas (mixed mesodermal tumors) of the uterus.	1	0.5	0	
4.	IUFD Study CRA: Almae Uy Anticipated accrual: 4	08-080	Misoprostol for Treatment of Fetal Death at 14-28 Weeks of Pregnancy, Inclusive, not Accompanied by Complete Expulsion of the Contents of the Uterus.	0	0	0	
5.	RTOG 0724 CRA: Basia Lukaszcyk Anticipated accrual: 3-5	09-207	A Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-risk Patients with Early-Stage Cervical Carcinoma following Radical Hysterectomy.	1	0.5	0	

Cancer Site: Head-Neck

1.	ECOG E-1305 CRA: Ariel Chavez Anticipated accrual: 10	09-019	A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer.	1	0	0	
2.	Ex. Study IRB# 06-231 CRA: Anticipated accrual:	06-231	Behavioral Assessment of Head and Neck Cancer Patients.				
3.	RTOG 0436 CRA: Almae Uy Anticipated accrual: 5-10	08-158	A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without Surgery.	1	0.5	0	
4.	RTOG 0920 CRA: Ariel Chavez Anticipated accrual: 10-15	10-021	A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab For Locally-Advanced Resected Head And Neck Cancer.				
5.	RTOG 1016 CRA: Ariel Chavez Anticipated accrual: 5-10	11-149	Phase III Trial Of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy In HPV-Associated Oropharynx Cancer. CC credits 0.5 - via supplemental RTOG 1016 QOL protocol	1	0	0	
6.	RTOG 1016 QOL CRA: Ariel Chavez Anticipated accrual:		Supplemental QOL protocol for RTOG 1016.	0	0.5	0	

Cancer Site: Liquid Tumors

1.	CALGB 10403 CRA: Wendy/Augustin Anticipated accrual: 5	09-159	An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia (ALL).	1	0	0	
2.	CALGB 10404 CRA: Wendy/Augustin Anticipated accrual: 5	09-169	A Randomized Phase II Study of Three Fludarabine/Antibody Combinations for Patients with Symptomatic Previously Untreated Chronic Lymphocytic Leukemia.	1	0	0	
3.	CALGB 50303 CRA: Wendy/Augustin Anticipated accrual: 10-15	10-084	Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas.	1	0	0	

	Protocol	IRB #	Description	Credits:	Treatm.	Control	F/U
4.	CALGB 50604 CRA: Augustin Haidau Anticipated accrual: 5	11-105	Phase II Trial of Response-Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin Lymphoma. * Additional 0.3 Tr. Cr. In case of supplemental CALGB 150805 protocol.	1	0	0	0
5.	SWOG S0535 CRA: Augustin Haidau Anticipated accrual: 2	09-168	A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemi.	1	0	0	0
6.	SWOG S0816 CRA: Wendy/Augustin Anticipated accrual: 2	10-054	A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma using Early Interim FDG-PET Imaging.	1	0	0	0

Cancer Site: Lung

1.	ECOG E-1505 CRA: Almae Uy Anticipated accrual: 5	09-017	A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥ 4 cm)-IIIA Non-Small Cell Lung Cancer (NSCLC).	1	0	0	0
2.	RTOG 0538 CRA: Almae Uy Anticipated accrual: 5	10-043	CALGB 30610 / RTOG 0538: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide.	1	0.5	0	0
3.	RTOG 0839 CRA: Almae Uy Anticipated accrual: 3	11-057	Randomized Phase II Study Of Pre-Operative Chemoradiotherapy +/- Panitumumab (Ind #110152) Followed By Consolidation Chemotherapy In Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer.				

Cancer Site: Multiple

1.	CALGB 70604 CRA: Vanessa Barrera Anticipated accrual: 10	09-141	A Randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer.	0	1	0	0
2.	Ex. Study IRB# 10-119 CRA: Anticipated accrual:	10-119	Oncology Appointment Compliance in Navigated vs. Non-Navigated Stroger Patients.	0	0	0	0
3.	SWOG S0702 CRA: Namrata Das Anticipated accrual: 10	10-208	A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment. * F/U credits: S0702-A (0.3 FU) For all assessment forms as outlined in protocol (Medical, Dental and Off-study). Credit is to be assigned at time of Off-Study form submission. S0702-B (0.5 FU) For confirmation of ONJ in patient. S0702-C (0.1 FU) For submission of 1st ONJ Assessment form as outlined in the protocol. S0702-D (0.1 FU) For 2nd submission of ONJ Assessment form as outlined in the protocol.	0	0.5	1	1

Cancer Site: Other

1.	ECOG E-1208 CRA: Karen Carter Anticipated accrual: 2	10-053	Liver Cancer. A Phase III Randomized Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion.	1	0	0	0
----	---	--------	--	---	---	---	---

Protocol	IRB #	Description	Credits	Treatm.	Control	F/U
Cancer Site: Prostate						
1. CCCWFU 98110	11-102	A Randomized Phase II Dose Finding Study of ArginMax for Its Effect on Erectile Function and Quality of Life in Survivors of Prostate Cancer Previously Treated with Radiotherapy.				
CRA: Basia Lukaszcyk						
Anticipated accrual:						
2. ECOG E-2809	11-058	Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy.				
CRA: Basia Lukaszcyk						
Anticipated accrual: 3						
3. RTOG 0534	08-062	A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (Support) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy.	1.5	0.5	0	
CRA: Basia Lukaszcyk						
Anticipated accrual: 3-5						
4. RTOG 0815	10-041	A Phase III Prospective Randomized Trial Of Dose-Escalated Radiotherapy With Or Without Short-Term Androgen Deprivation Therapy For Patients With Intermediate-Risk Prostate Cancer. *** 0.5 CC credits for QOL.	1	0.5	0	
CRA: Basia Lukaszcyk						
Anticipated accrual: 5						

Cancer Site: Renal

1. CALGB 150907		Sub-study of CALGB 90802 (for plasma and urine samples).	0.5	0	0	
CRA: Wendy A. Rogowski						
Anticipated accrual: 0						
2. CALGB 60903		Sub-study of CALGB 90802	0.1	0	0	
CRA: Wendy A. Rogowski						
Anticipated accrual: 0						
3. CALGB 90802	10-225	Randomized Phase III Trial Comparing Everolimus Plus Placebo Versus Everolimus Plus Bevacizumab For Advanced Renal Cell Carcinoma Progressing After Treatment With Tyrosine Kinase Inhibitors.	1	0	0	
CRA: Wendy A. Rogowski						
Anticipated accrual: 5						